Emergency Medicine

HIV / AIDS

Medical News

Primary Care

Surgery

Home » Dermatology, Medical News

Provectus Pharmaceuticals Completes Patient Accrual In Initial Phase 2 Study Of PH-10 For Atopic Dermatitis

Submitted by on Thursday, 2 July 2009No Comment

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual for its Phase 2 study of PH-10 for atopic dermatitis.

Original post: 
Provectus Pharmaceuticals Completes Patient Accrual In Initial Phase 2 Study Of PH-10 For Atopic Dermatitis

Found something that might interest others? Share!

You may also like:

Leave your response!

Add your comment below, or trackback from your own site. You can also subscribe to these comments via RSS.

Be nice. Keep it clean. Stay on topic. No spam.

You can use these tags:
<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

This is a Gravatar-enabled weblog. To get your own globally-recognized-avatar, please register at Gravatar.

*
To prove you're a person (not a spam script), type the security word shown in the picture. Click on the picture to hear an audio file of the word.
Click to hear an audio file of the anti-spam word